Related Experiment Video
Updated: Sep 15, 2025

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists
Published on: November 15, 2013
Structural basis of PPARγ-mediated transcriptional repression by the covalent inverse agonist FX-909
Zane T Laughlin1, Liudmyla Arifova1,2, Paola Munoz-Tello1
1Department of Biochemistry, Vanderbilt University, Nashville, Tennessee, United States 37232.
Abstract:
Hyperactivation of peroxisome proliferator-activated receptor gamma (PPARγ)-mediated transcription promotes tumor growth in urothelial (bladder) cancer, which can be inhibited by pharmacological compounds that repress PPARγ activity. FX-909 is a covalent PPARγ inverse agonist currently in phase 1 clinical trials for advanced solid malignancies including muscle-invasive bladder cancer. Here, we compared the mechanism of action of FX-909 to other covalent inverse agonists including T0070907, originally reported more than 20 years ago and misclassified as an antagonist, and two recently reported improved covalent inverse agonist analogs, SR33068 and BAY-4931. Functional profiling and NMR studies reveal that FX-909 displays improved corepressor-selective inverse agonism and better stabilizes a transcriptionally repressive PPARγ LBD conformation compared to T0070907. The crystal structure of PPARγ LBD cobound to FX-909 and NCoR1 corepressor peptide reveals a repressive conformation shared by other covalent inverse agonists. These findings build on recent studies highlighting the pharmacological significance and clinical relevance of transcriptionally repressive PPARγ inverse agonists.
Insights
FX-909, a novel drug, effectively inhibits bladder cancer growth by repressing peroxisome proliferator-activated receptor gamma (PPARγ) activity. This compound shows improved selectivity and stabilization of a transcriptionally repressive PPARγ conformation.
Area of Science:
- Molecular Biology
- Oncology
- Pharmacology
Background:
- Hyperactivation of peroxisome proliferator-activated receptor gamma (PPARγ) drives urothelial cancer growth.
- Pharmacological inhibition of PPARγ is a therapeutic strategy for bladder cancer.
- FX-909 is an investigational covalent PPARγ inverse agonist for advanced solid tumors, including bladder cancer.
Purpose of the Study:
- To compare the mechanism of action of FX-909 with other covalent PPARγ inverse agonists.
- To elucidate the structural basis for FX-909's selective inverse agonism.
- To highlight the clinical relevance of transcriptionally repressive PPARγ inverse agonists.
Main Methods:
- Functional profiling assays.
- Nuclear Magnetic Resonance (NMR) spectroscopy.
- Crystallography of the PPARγ ligand-binding domain (LBD) complexed with FX-909 and a corepressor peptide.
Main Results:
- FX-909 exhibits enhanced corepressor-selective inverse agonism compared to T0070907.
- FX-909 more effectively stabilizes a transcriptionally repressive PPARγ LBD conformation.
- Structural analysis revealed a shared repressive conformation among covalent inverse agonists.
Conclusions:
- FX-909 demonstrates improved pharmacological properties as a PPARγ inverse agonist.
- The findings support the development of transcriptionally repressive PPARγ inverse agonists for cancer therapy.
- FX-909's mechanism is crucial for its potential in treating muscle-invasive bladder cancer.
More Related Videos
09:07Prediction and Validation of Gene Regulatory Elements Activated During Retinoic Acid Induced Embryonic Stem Cell Differentiation
Published on: June 21, 2016
10:28Repressing Gene Transcription by Redirecting Cellular Machinery with Chemical Epigenetic Modifiers
Published on: September 20, 2018
Related Concept Videos
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Co-activators and Co-repressors
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Master Transcription Regulators
RNA Polymerase II Accessory Proteins
Prokaryotic Transcriptional Activators and Repressors
Transcription of prokaryotic...